Macías-Murelaga B, Ruiz M, Bascarán L, Gibelalde A, Aldazabal M, Irigoyen C
Servicio de Oftalmología, Hospital Donostia, Donostia-San Sebastián, España.
Arch Soc Esp Oftalmol. 2013 Nov;88(11):445-9. doi: 10.1016/j.oftal.2012.12.011. Epub 2013 Apr 3.
Prospective observational study including 10 patients (age range: 27-74 years) with recurrent retinal detachment (RD) and proliferative vitreoretinopathy (PVR) and 2.8 mean unsatisfactory previous surgeries. Densiron® was injected in all patients, with surgical retinectomy being required in 70% of them. Minimum follow-up time was 12 months.
The mean length of time before Densiron® withdrawal was 4 months. Three patients (30%) presented with a new RD. The main complication detected was cataract development. No relationship was found between re-detachments and tamponade time, baseline disease or RD evolution time. Densiron® may be a good option in cases of recurrent RD in which previous treatment with scleral buckle, gas and/or 1,000/5,000 silicone oils has proven to be unsatisfactory.
前瞻性观察性研究，纳入10例复发性视网膜脱离（RD）和增殖性玻璃体视网膜病变（PVR）患者（年龄范围：27 - 74岁），既往手术平均2.8次效果不佳。所有患者均注射了Densiron®，其中70%的患者需要进行手术视网膜切除术。最短随访时间为12个月。
Densiron®取出前的平均时间为4个月。3例患者（30%）出现了新的视网膜脱离。检测到的主要并发症是白内障形成。在再脱离与填塞时间、基线疾病或视网膜脱离演变时间之间未发现相关性。对于既往巩膜扣带术、气体和/或1000/5000硅油治疗效果不佳的复发性视网膜脱离病例，Densiron®可能是一个不错的选择。
